DVL1 and colorectal carcinoma: Moreover, the study also showed that silencing DVL1-3 could re-sensitise CRC cells to vincristine, 5-FU and oxaliplatin, suggesting that DVL could be a potential therapeutic target in multidrug-resistant CRC.